Ireland· IE-PA-EU/1/07/437/003-004
Ivemend 150 mg Powder for solution for infusion
A aprepitant product containing fosaprepitant dimeglumine, registered in Ireland by Merck Sharp & Dohme BV,. The same ATC class is registered in 17 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Aprepitant is registered in 17 of 19 countries.
Countries holding a registration under ATC A04AD12 (aprepitant), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Aprepitant · ATC A04AD12
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aprepitant costs, country by country.
Normalised to the WHO defined daily dose (165 mg), the median price runs from $0.40 in Finland to $157.48 in United States — a ×394 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Aprepitant · price per daily dose (165 mg)
USD · FX 28 Sept 2026
- US United States$157.48 (acquisition cost)
- CH Switzerland$73.26
- FR France$33.15
- FI Finland$0.40
The record
At a glance
HPRA (Ireland)- Active substance
- Fosaprepitant dimeglumine
- Manufacturer
- Merck Sharp & Dohme BV,
- Country
- Ireland (IE)
- ATC code
- A04AD12
- ATC class
- Aprepitant
- Defined daily dose
- 165 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/07/437/003-004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
583 interactions on record for aprepitant.
Graded by severity as the source publishes them — 73 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aprepitant · interactions on record
583 records
- 73 severe
- 380 moderate
- 25 minor
- 104 info
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- LonafarnibA16AX20severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aprepitant in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaIVEMENDMerck Sharp & Dohme B.V., Haarlem
- FinlandFosaprepitant AccordAccord Healthcare B.V.
- BelgiumIvemend 150 mgMerck Sharp & Dohme
- United StatesEMENDMerck Sharp & Dohme LLC
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Spain · Fosaprepitant Zentiva
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/970157fa-bb01-4609-b01b-22d606a08ff8 GET /v1/drugs/970157fa-bb01-4609-b01b-22d606a08ff8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for infusion",
"routes": null,
"source": "hpra",
"atc_all": [
"A04AD",
"A04AD12"
],
"strength": null,
"pa_number": "EU/1/07/437/003-004",
"substances": [
"Fosaprepitant dimeglumine"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "31/08/2010",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about aprepitant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.